An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
Cardiff, New South Wales, Australia, 2285
- Pendlebury Research
-
Maroubra, New South Wales, Australia, 2035
- Australian Clinical Research Network
-
St. Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
Wollongong, New South Wales, Australia, 2500
- Illawara Diabetes Service
-
-
Queensland
-
Herston, Queensland, Australia, 4006
- Q-Pharm
-
Ipswich, Queensland, Australia, 4305
- Ipswich Research Institute
-
Sherwood, Queensland, Australia, 4075
- Austrials
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- CMAX
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Box Hill Hospital
-
Fitzroy, Victoria, Australia, 3065
- St. Vincent's Hospital
-
Geelong, Victoria, Australia, 3220
- Barwon Health
-
Heidelberg West, Victoria, Australia, 3081
- Austin Health
-
Malvern East, Victoria, Australia, 3145
- Emeritus Research
-
Melbourne, Victoria, Australia, 3004
- Baker IDI Heart and Diabetes Institute
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Keogh Institute for Medical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Obese with BMI ≥30 kg/m2
- Type 2 diabetes mellitus
- HbA1c of 7-11%
- Fasting glucose <15.5 mmol/L
- Treated with diet and exercise alone or with a stable regimen of metformin, sulfonylurea, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT-2 inhibitor or any combination of these agents
- Female subjects must be surgically sterile, post-menopausal or using long-acting contraception, which includes intrauterine devices or use of an implanted or injectable contraceptive
Exclusion Criteria:
- Current or recent use of insulin
- Severe hypoglycemia within the prior 6 months
- Metabolic disorders or genetic disorders linked to obesity (e.g., Prader-Willi Syndrome)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ZGN-440 Injectable Suspension (1.2mg)
ZGN-440 for Injectable Suspension
|
Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
Other Names:
|
|
Experimental: ZGN-440 Injectable Suspension (1.8mg)
ZGN-440 for Injectable Suspension
|
Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
Other Names:
|
|
Placebo Comparator: Placebo
ZGN-440 Placebo for Injectable Suspension
|
Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in body weight
Time Frame: Baseline to Week 26
|
Baseline to Week 26
|
|
Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations
Time Frame: Baseline to Week 26 and Week 52
|
Baseline to Week 26 and Week 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight
Time Frame: Baseline to Week 52
|
Baseline to Week 52
|
|
|
Change in fasting glycemic parameters
Time Frame: Baseline to Week 26 and Week 52
|
HbA1c, plasma glucose
|
Baseline to Week 26 and Week 52
|
|
Change in cardiometabolic parameters
Time Frame: Baseline to Week 26 and Week 52
|
Blood pressure, lipid concentrations, hs-CRP
|
Baseline to Week 26 and Week 52
|
|
Change in Patient Reported Outcomes (PRO) scores
Time Frame: Baseline to Week 26 and Week 52
|
Baseline to Week 26 and Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ZAF-203
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.